Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Connecticut
Clinical trial register · United States · industry-sponsored

Clinical Trials in Connecticut, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9132 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 10 Oct 2026, 03:16 UTC
9132
Studies in scope
industry-sponsored, all four open statuses
4964
Recruiting now
open to new participants
2194
Lead sponsors
across recruiting studies
Top states
California 64 Florida 51 Illinois 32 Georgia 26 Connecticut 25
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Eli Lilly and Company59 AstraZeneca58 AbbVie48 Merck Sharp & Dohme LLC40 Janssen Research & Development, LLC39 Clear sponsor filter
State
California64 Florida51 Illinois32 Georgia26 Connecticut25
All 45 states
Target enrolment
to

Trials with a site in Connecticut

25 of 9132 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Amgen
Phase 3
3,200
Alabama, California, Connecticut, Florida, Georgia, Hawaii, Idaho, Illinois
2026-07-23
Recruiting
Amgen
Phase 3
304
California, Colorado, Connecticut, Florida, Illinois, Indiana, Maryland, Massachusetts
2026-05-27
Recruiting
Amgen
Phase 3
406
Connecticut, Florida, Kansas, Maryland, Pennsylvania, Texas
2026-03-23
Recruiting
Amgen
Phase 3
750
Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Illinois
2025-11-28
Recruiting
Amgen
Phase 3
11,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2025-08-22
Active, closed
Amgen
Phase 3
350
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2025-08-18
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
DrugMaridebart cafraglutide
Amgen
Phase 3
5,056
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Idaho
2025-06-25
Active, closed
Amgen
Phase 1
29
California, Connecticut, Florida, Massachusetts, Missouri, North Dakota, Ohio, South Dakota
2025-05-16
Active, closed
Amgen
Phase 3
1,105
Alabama, Arizona, California, Connecticut, Florida, Illinois, Indiana, Iowa
2025-03-17
Active, closed
Amgen
Phase 3
3,853
Alabama, Arizona, California, Connecticut, Florida, Georgia, Hawaii, Idaho
2025-03-12
Active, closed
Amgen
Phase 2
252
California, Connecticut, Florida, Illinois, Minnesota, New York, North Carolina, Pennsylvania
2025-02-26
Active, closed
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
NCT06700343Relapsing-remitting Multiple Sclerosis (RRMS)
DrugOcrelizumab
Amgen
Phase 3
152
Alabama, Arizona, California, Colorado, Connecticut, Florida, Hawaii, Illinois
2025-01-13
Active, closed
Amgen
Phase 2
61
California, Colorado, Connecticut, District of Columbia, Louisiana, Michigan, Tennessee, Texas
2024-12-26
Active, closed
Amgen
Phase 1
49
California, Colorado, Connecticut, Minnesota, Missouri, Nevada, New York, Oklahoma
2024-09-17
Recruiting
Amgen
Phase 3
450
Arizona, California, Connecticut, Florida, Georgia, Illinois, Kentucky, Michigan
2024-07-17
Active, closed
Amgen
Phase 3
563
Alabama, California, Connecticut, Georgia, Illinois, Indiana, Louisiana, Massachusetts
2024-06-05
Active, closed
Amgen
Phase 1
120
California, Colorado, Connecticut, Illinois, Indiana, Kentucky, Massachusetts, Missouri
2024-05-29
Active, closed
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
DrugTarlatamab
Amgen
Phase 3
404
California, Connecticut, Florida, Kentucky, Louisiana, New Jersey, New York, North Carolina
2024-02-20
Active, closed
Amgen
Phase 3
7,297
Alabama, Alaska, Arizona, California, Colorado, Connecticut, District of Columbia, Florida
2022-12-14
Active, closed
EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
NCT05284747Cardiovascular Disease, Myocardial Infarction, Stroke, Coronary Revascularization
DrugsRepatha·Evolocumab
Amgen
Phase 4
6,019
Alabama, Arizona, California, Colorado, Connecticut, Florida, Idaho, Illinois
2022-10-26
Active, closed
Myasthenia Gravis Inebilizumab Trial
NCT04524273Myasthenia Gravis
DrugInebilizumab
Amgen
Phase 3
238
California, Connecticut, District of Columbia, Florida, Kansas, North Carolina, Ohio, Pennsylvania
2020-10-15
Recruiting
Amgen
Phase 1
479
California, Colorado, Connecticut, Georgia, Indiana, Kansas, Louisiana, Missouri
2020-03-04
Active, closed
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
NCT04185883Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
DrugsBI 1701963·TNO155·Sotorasib·Afatinib
Amgen
Phase 1
610
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2019-12-17
Active, closed
Amgen
Phase 3
457
California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois, Indiana
2019-07-19
Active, closed
Amgen
Phase 1
269
California, Connecticut, Florida, Georgia, Illinois, Louisiana, Maryland, Michigan
2017-12-26
Rows per page Showing 1–25 of 25
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 October 2026. https://priyalifescience.com/clinical-trials-usa/state/connecticut

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,132 studies in total at the last sync on 10 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 25 of those studies with a site in Connecticut that also match the filters currently applied.

How many clinical trials are recruiting in Connecticut?

8 of the 25 studies on this page are recruiting new participants as of the 10 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 17 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Connecticut), 25 studies
PhaseStudiesRecruitingShare
Phase 316764%
Phase 16124%
Phase 2208%
Phase 4104%

Most active sponsors

Lead sponsors with the most studies (Connecticut)
Lead sponsorStudiesRecruiting
Amgen258
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.